TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Proportion of Subjects Completing Intervention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Incidence of Falls
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of quadriceps femoris parts thickness measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change of quadriceps femoris parts pennation angles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Maximum Dose Tolerated
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: American Urologic Association Symptom Score (AUASS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Concentration of Hemoglobin A1C (HbA1C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Prevalence of Atherosclerosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of Reclassification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Compare FRS to the CAC - At Least One Additional Risk Factor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and Tolerability
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Plasma Glucose (MPG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Capillary Plasma Glucose Measurements Within the Range of 71 to 179 mg/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change of pressure pain threshold (PPT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cerebral blood flow in the median cerebral artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: number of patients operated for gastric GIST
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Understanding of prescription medication
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Patients With Adverse Events or Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Patients With Dose Limiting Toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Clinician Administered PTSD Scale for DSM-5 (CAPS-5)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: NF-1 gene expression pattern
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Dating abuse perpetration
Endpoint domain: Adverse events/effects
Primary endpoint: Cognition and memory measured by ADAS-cog
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Global function measured by CIBIC-plus
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Days until closure of the corneal wound
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stop Signal task performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Improvement (Yale-Brown Obsessive Compulsive Scale/Y-BOCS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional independency at 3 months
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Incidence of DRA-ACC
Endpoint domain: Adverse events/effects
Primary endpoint: Safety of AVX-012 ophthalmic solution
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy in treating symptoms of dry eye
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MRS Correlation with Treatment Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to maximum observed serum concentration (Tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to elimination half-life (T1/2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration versus time curve (AUC0-last)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: feasibility of the combination of Rituximab with Gemcitabin/cisplatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinically significant hypoglycaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: number of diabetic patients up to date with vaccinations
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Numeric Rating Scale (NRS)
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Performance of thorough skin-self examination (SSE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Time to first Major Adverse Cardiac Event (MACE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percent Change in Lumbar Spine Bone Mineral Density (BMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Major allergen sensitization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: number of patients weaned from the ventilator
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: number of patients discharged from ICU
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Total metabolites detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of conventionally detected hypoglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Sensitivity and specificity of patch performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in mean iron content in specific brain nuclei
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cognition Fluid Composite Score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Adverse neonatal outcome
Endpoint domain: Adverse events/effects
Primary endpoint: liver iron concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of E7080
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Daily survey/task adherence
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Oura adherence
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Garmin adherence
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: perioperative outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improve of ALI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite cardiovascular outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total radioactivity in plasma (AUC0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total radioactivity in plasma (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total radioactivity in plasma (Tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Combined incidence of biopsy proven subclinical rejection and biopsy proven clinical acute rejection
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Developed Positive Binding Anti-ADAMTS13 and Inhibitory Anti-ADAMTS13 Antibodies to TAK-755
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Serum Progesterone Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Ovarian Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change of Pulmonary Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change of Aerosol deposition in the lungs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change of Regional pulmonary ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Muscle protein synthetic rate (FSR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heart rate and blood pressure at rest and during recall of caregiver situation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Salivary cortisol upon awakening, 30 minutes later, and prior to going to bed at night
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Center for Epidemiological Studies Depression scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cmax (maximum reach concentration)/ MIC (Minimum inhibitory concentration)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in severity and frequency of physical violence
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Area Under the Concentration-time Curve From 0 to Infinity (AUC0-∞)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apparent Total Body Clearance (CL/F)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in C reactive protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in flow-mediated dilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 13C-DHA incorporation into plasma lipids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: beta-oxidation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants With Observed Local Erythema
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Observed Local Edema
Endpoint domain: Adverse events/effects
Primary endpoint: Patient's perception of oral comfort
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Oral health (clinical evaluation)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Pain Intensity Numeric Rating Scale (NRS) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Western Ontario and McMaster Universities (WOMAC® 3.1) Osteoarthritis Index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Patient's Global Impression of Change (PGIC)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: antimyeloma activity as measured by the paraprotein
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: toxicity of simvastatin in combination with chemotherapy
Endpoint domain: Adverse events/effects
Primary endpoint: TVF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in health-related quality of life (EQ-5D-5L)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Spontaneous adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Blood pressure and heart rate measured in sitting position
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: International Prostate Symptom Score (IPSS) and quality of life index
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Incidence of Study Product-Emergent Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum Tolerated Dose
Endpoint domain: Adverse events/effects
Primary endpoint: Safety of vector
Endpoint domain: Adverse events/effects
Primary endpoint: Bone volume changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Negative predictive value of transcranial doppler
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Ex Vivo Frequency of Melan-A Specific CD8+T Cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: In Vitro Frequency of MAGE A3.DP4-specific CD4+ T Cells Producing Interferon-gamma (IFN-γ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: In Vitro Frequency of MAGE A3.DP4-specific CD4+ T Cells Producing Tumor Necrosis Factor-alpha (TNF-α)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in COPD Clinical Impact
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease condition measured by modified Rodnan skin score (MRSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete mucosal visualization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stabilization of hematocrit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Platelet count maintenance in a therapeutic range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: 28-day Mortality
Endpoint domain: Mortality/survival
Primary endpoint: Improvement of Cardiac Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Safety and tolerability parameters
Endpoint domain: Adverse events/effects
Primary endpoint: Average salivary flow rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfactory Pain Management
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of Sensor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Total Clinical Score (TCS) of clinical symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Global Improvement Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Colistin elimination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: neuropsychological test scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: whole blood gene regulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Serum Phosphorus Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: circulating tumor cells level changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incidence of Grade 4 study related toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Effectiveness of autoHSCT in combination with FMT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of risk behavior
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: Echogenicity ratio of the biceps brachii tendon
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in State-Trait Anxiety Inventory score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of participants with abnormal laboratory test results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in electro-magnetic spectra
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression-Free Survival Rate at 12 Weeks
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants With Adverse Events Based on Severity
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical Global Impression Scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Successful implantation (aneurysm exclusion and graft patency)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Arm Activity Measure (ArmA)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Chedoke Arm and Hand Activity Inventory-7 (CAHAI-7)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Irritable Bowel Syndrome Symptom Severity (IBS-SSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Bristol stool form scale (BSFS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Patient Related Ulnar Nerve Evaluation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: PASI 75 Achievement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in Drooling Severity and Frequency Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Drooling impact scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Longitudinal Myocardial Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pain Intensity Measure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: feasibility and tolerance of preoperative therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Abdominal aortic aneurysm growth and rupture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change in NIH-CPSI total score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Time to effective analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence and nature of laboratory abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incidence, nature, and severity of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Marge assessment immediately after resection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Efficacy of thalamic stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Opioid Consumption
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Tendon stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Clinic systolic blood pressure lowering
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cardiovagal Baroreflex
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cognitive ability
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Increase in brain GABA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Increase in brain NTP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of Participants Assessed as Very Much Improved or Much Improved
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: ART uptake and adherence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective pain assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with adverse events per type
Endpoint domain: Adverse events/effects
Primary endpoint: Plasma concentration of TMC647055
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wong-Baker FACES® Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Children's Fear Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percent Change in Pulmonary Vascular Resistance (PVR) at 0.5 Hour Post-CPB
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mortality: Number of Participants Died During Surgery and Initial Hospitalization
Endpoint domain: Mortality/survival
Primary endpoint: oocyte survival rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Time to Disease Progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Integration of mesenchymal stem cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Metabolic analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Neonatal outcome
Endpoint domain: Mortality/survival
Primary endpoint: angle of contracture of the affected fingers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Right ventricular failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: microvascular reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Diffusion capacity for CO (DLCO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Pain limiting usual activities
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Physical function (PCS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Safety and efficacy of incontinence and prolapse procedures
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in Colon Pathology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Neuropsychological test results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cytokine profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes